BBIO - BridgeBio releases new phase 2 results for infigratinib for achondroplasia
2024-06-04 11:42:04 ET
More on BridgeBio Pharma
- BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
- BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident
- BridgeBio reports additional positive data for acoramidis in ATTR-CM
- Cantor picks 14 undervalued biotech stocks worth a second look
- Seeking Alpha’s Quant Rating on BridgeBio Pharma